United States Últimas notícias

GameStop (NYSE:GME) reported a second-quarter operating income of $160.2 million driven by a 57% year-over-year increase in collectibles sales.

Quantum Cyber (NASDAQ:QUCY) acquired a Lambda Hyperplane 8-A100 AI compute cluster powered by NVIDIA A100 Tensor Core GPUs to support its autonomous defense platforms and AI development efforts.

BioVie (NASDAQ:BIVI) advanced regulatory discussions with the U.S. FDA for a Phase 3 development program evaluating bezisterim in Parkinson’s disease following Phase 2 SUNRISE-PD results.

GE Aerospace (NYSE:GE) agreed to acquire Consolidated Precision Products (CPP) for $11.75 billion, expanding its aerospace casting capabilities for commercial aviation, defense, and power markets.

AEVEX Corp. (NYSE:AVEX) completed its acquisition of BlackSea Technologies, adding unmanned surface and subsea vessel capabilities to its autonomous defense systems business.

Inhibrx Biosciences (NASDAQ:INBX) reported Phase 2 HexAgon trial results showing INBRX-106 combined with pembrolizumab achieved a 48.3% confirmed objective response rate in first-line head and neck cancer patients.

Samantha Dart, co-head of global commodities research at Goldman Sachs, says that gasoline and diesel prices can remain elevated into "the whole of next year" as tightness in refining capacity is not being resolved. She speaks on "Bloomberg Surveillance."

Abbott (NYSE:ABT) received U.S. FDA approval for its TactiFlex Duo Ablation Catheter, Sensor Enabled, a device designed to treat atrial fibrillation using pulsed field ablation and radiofrequency energy technologies.

AstraZeneca (NASDAQ:AZN) reported Phase III OBERON and TITANIA trial results showing tozorakimab reduced moderate and severe COPD exacerbations across broad patient populations while patients remained on standard inhaled treatment.

enGene Therapeutics (NASDAQ:ENGN) reported regulatory and clinical progress for detalimogene, including plans for a U.S. FDA pre-BLA meeting and initiation of a Biologics License Application submission in the fourth quarter of 2026.

IonQ (NYSE:IONQ) expects full-year 2026 revenue of $450 million–$460 million following its acquisition of SkyWater Technology, with the outlook including SkyWater’s contribution from July 31 through December 31, 2026.

Adlai Nortye (NASDAQ:ANL) dosed the first patient in Australia in a global Phase I trial evaluating AN4035, an antibody-drug conjugate designed to treat CEACAM5-enriched RAS-addicted solid tumors.